Skip to Content

'
Stacy L. Moulder, M.D., M.S.C.I.

Present Title & Affiliation

Primary Appointment

Assistant Professor, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

Assistant Professor, Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, TX

Education & Training

Degree-Granting Education

2002 Vanderbilt University, Nashville, TN, MS, Masters of Science in Clinical Investigation
1995 University of Mississippi School of Medicine, Jackson, MS, MD, Medicine
1990 Mississippi State University, Jackson, MS, BS, Graduated Cum Laude, Chemistry

Postgraduate Training

2001-2002 Fellowship, Oncology Research, Vanderbilt University Medical Center, Nashville, TN
1998-2001 Fellowship, Hematology/Oncology, Vanderbilt University Medical Center, Nashville, TN
1995-1998 Internship and Residency, Internal Medicine, University of Mississippi Medical Center, Jackson, MS

Board Certifications

11/2002 American Board of Internal Medicine, Medical Oncology
8/1998 American Board of Internal Medicine
12/1995 United States Medical Licensing Examination
8/1994 United States Medical Licensing Examination
6/1993 United States Medical Licensing Examination

Honors and Awards

2002 Career Development Award, American Society of Clinical Oncology
2001 Fellowship Award, American Association for Cancer Research
2001 Merit Award, American Society of Clinical Oncology
2001 Star Fellow Award, Vanderbilt Hematology Oncology
2001 Trainee Travel Award, American Society of Clinical Investigation
2000 Star Fellow Award, Vanderbilt Hematology Oncology
1998-2002 Harry Joyce Fellowship, Vanderbilt University Medical Center
1994 Associated Student Body Vice President, University of Mississippi School of Medicine
1992 Medical Student Research Fellowship, University of Mississippi Medical Center

Selected Publications

Peer-Reviewed Original Research Articles
1. Liedtke C, Broglio K, Moulder S, Hsu L, Kau SW, Symmans WF, Albarracin C, Meric-Bernstam F, Woodard W, Theriault R, Kiesel L, Hortobagyi GN, Pusztai L, Gonzalez-Angulo AM.. "Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer". Ann Oncol, 7/2009. PMID: 19596702.
2. Moulder S, Dhillon N, Ng C, Hong D, Wheler J, Naing A, Tse S, La Paglia A, Dorr R, Hersh E, Boytim M, Kurzrock R. A phase I trial of imexon, a pro-oxidant, in combination with docetaxel for the treatment of patients with advanced breast, non-small cell lung and prostate cancer. Invest New Drugs, 6/2009. PMID: 19499186.
3. Kazi A, Carie A, Blaskovich MA, Bucher C, Thai V, Moulder S, Peng H, Carrico D, Pusateri E, Pledger WJ, Berndt N, Hamilton A, Sebti SM. "Blockade of protein geranylgeranylation inhibits Cdk2-dependent p27Kip1 phosphorylation on Thr187 and accumulates p27Kip1 in the nucleus: implications for breast cancer therapy". Mol Cell Biol. 29(8):2254-63, 4/2009.
4. Sparano JA, Moulder S, Kazi A, Coppola D, Negassa A, Vahdat L, Li T, Pellegrino C, Fineberg S, Munster P, Malafa M, Lee D, Horschander S, Hopkins U, Hershman D, Wright JJ, Kleer C, Meraiver S, Sebti SM.. "Phase II trial of tipifarnib plus neoadjuvant doxorubicin-cyclophosphamide in patients with clinical stage IIB-IIIC breast cancer". Clin Cancer Res 15(8):2942-8, 4/2009. PMID: 19351752.
5. Moulder S, Holmes F, Tolcher A, Thall P, Broglio K, Valero V, Buzdar A, Arbuck S, Seidman A, Hortobagyi G. A randomized phase II trial comparing 3-hour versus 96-hour infusion schedules of paclitaxel for the treatment of metastatic breast cancer. Cancer, accepted for publication, 2009.
6. Moulder SL, Symmans WF, Booser DJ, Madden TL, Lipsanen C, Yuan L, Brewster AM, Cristofanilli M, Hunt KK, Buchholz TA, Zwiebel J, Valero V, Hortobagyi GN, Esteva FJ. Phase I/II study of G3139 (Bcl-2 antisense oligonucleotide) in combination with doxorubicin and docetaxel in breast cancer. Clin Cancer Res 14(23):7909-7916, 12/2008. PMID: 19047121.
7. Moulder SL, Valkov N, Neuger A, Choi J, Lee JH, Minton S, Munster PN, Horton J, Gump J, Lacevic M, Lush R, Sullivan D. "Phase 2 study of gemcitabine and irinotecan in metastatic breast cancer with correlatives to determine topoisomerase l localization as a predictor of response". Cancer 113(10):2646-54, 11/2008.
8. Arteaga CL, O'Neill A, Moulder SL, Pins M, Sparano JA, Sledge GW, Davidson NE. "A phase I-II study of combined blockade of the ErbB receptor network with trastuzumab and gefitinib in patients with HER2 (ErbB2)-overexpressing metastatic breast cancer". Clin Cancer Res 14(19):6277-83, 10/2008.
9. Camacho LH, Marubio L, Purdom MA, Leonard D, Hong DS, Moulder S, Pilat SR, Kurzrock R. "Improving the institutional submission and approval process for clinical research protocols in oncology". J Clin Oncol 25(12):1632-3, 4/2007. PMID: 17443009.
10. Munster PN, Britten CD, Mita M, Gelmon K, Minton SE, Moulder S, Slamon DJ, Guo F, Letrent SP, Denis L, Tolcher AW. "First study of the safety, tolerability, and pharmacokinetics of CP-724, 714 in patients with advanced malignant solid HER2-expressing tumors". Clin Cancer Res 13(4):1238-45, 2/2007. PMID: 17317835.
11. Sparano JA, Moulder S, Kazi A, Vahdat L, Li T, Pellegrino C, Munster P, Malafa M, Lee D, Hoschander S, Hopkins U, Hershman D, Wright JJ, Sebti SM. "Targeted inhibition of farnesyltransferase in locally advanced breast cancer: a phase I and II trial of tipifarnib plus dose-dense doxorubicin and cyclophosphamide". J Clin Oncol 24(19):3013-8, 7/2006. PMID: 16769985.
12. Moulder SL, Mahany JJ, Lush R, Rocha-Lima C, Langevin M, Ferrante KJ, Bartkowski LM, Kajiji SM, Noe DA, Paillet S, Sullivan DM. "A phase I open label study of the farnesyltransferase inhibitor CP-609, 754 in patients with advanced malignant tumors". Clin Cancer Res 10(21):7127-35, 11/2004. PMID: 15534083.
13. Moulder SL, Arteaga CL. "A phase I/II Trial of trastuzumab and gefitinib in patients with Metastatic Breast Cancer that overexpresses HER2/neu (ErbB-2)". Clin Breast Cancer 4(2):142-145, 6/2003. PMID: 12864943.
14. Moulder SL, Yakes FM, Muthuswamy SK, Bianco R, Simpson JF, Arteaga CL. "Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo". Cancer Res 61(24):8887-95, 12/2001. PMID: 11751413.
15. Moulder SL, Roth BJ. "Systemic chemotherapy for urothelial transitional cell carcinoma: an overview of toxicity.". Semin Urol Oncol 19(3):194-201, 8/2001. PMID: 11561987.

Invited Articles
1. Moulder SL, Craft BS, Hortobagyi GN. "Inhibition of receptor tyrosine kinases in combination with chemotherapy for the treatment of breast cancer". Anticancer Agents Med Chem 8(5):481-7, May-Jun, 6/2008. PMID: 18537531.
2. Moulder SL.. "Ixabepilone for the treatment of taxane-refractory breast cancer". Future Oncol 4(3):333-40, May-Jun, 6/2008. PMID: 18518758.
3. Moulder S, Hortobagyi GN. "Advances in the treatment of breast cancer". Clin Pharmacol Ther 83(1):26-36, May-Jun, 1/2008. PMID: 18091763.
4. Craft BS, Hortobagyi GN, Moulder SL.. "Adjuvant biologic therapy for breast cancer". Cancer J 13(3):156-61, May-Jun, 6/2007. PMID: 17620764.
5. Arteaga CL, Moulder SL, Yakes FM. "HER (erbB) tyrosine kinase inhibitors in the treatment of breast cancer". Semin Oncol 29(3 Suppl 11):4-10, 6/2002. PMID: 12138392.

Abstracts
1. Moulder SL, Rivera E, Ensor J, Gonzalez-Angulo A, Cristofanilli M, Booser D, Giordano S, Brewster A, Hortobagyi G, Tran H. "Phase I trial of escalating dose of weekly everolimus (RAD001) in combination with docetaxel for the treatment of metastic breast cancer (MBC)". J Clin Oncol, 2009 ASCO Annual Meeting 27(15S) (#1066), 2009.
2. Moulder SL, Dhillion N, Hong DS, Ng CS, Camacho LH, Hersh EM, Grenier KA, Boytim ML, Dorr RT, Kurzrock R. "A phase I study of imexon in combination with docetaxel (DOC) for the treatment of patients with breast, lung and prostate cancer". J Clini Oncol, 2008 ASCO Annual Meeting (May 20 suppl) 26 (#3589), 2008.
3. Moulder SL, Wang M, Gradishar W, Perez EA, Sparano J, Pins M, Sledge G. "A phase II trial of trastuzumab, weekly ixabepilone and carboplatin (TIC) in patients with HER2/neu-positive (HER2+) metastatic breast cancer (MBC): A trial coordinated by the Eastern Cooperative Oncology Group (E2103). 2007 Breast Cancer Symposium (#152), 2007.
4. Moulder SL, O'Neill A, Arteaga C, Pins M, Sparano J, Sledge G, Davidson N. "Final results of ECOG1100: A phase I/II study of combined blockade of the ErbB receptor network in patients with HER2-overexpressing metastatic breast cancer (MBC)". J Clin Oncol, 2007 ASCO Annual Meeting 25(18S) (#1033), ASCO Ann Meeting Proc, Part I (June 20 Suppl), 2007.
5. Moulder SL, Valkov N, Minton S, Munster P, Gump J, Lacevic M, Rocha-Lima C, Horton J, Lush R, Sullivan D. "A single arm phase II trial of gemcitabine (G) and irinotecan (I) in metastatic breast cancer: Can localization of topoisomerase I (topo I) predict response to topo I inhibitors? J Clin Oncol, 2006 ASCO Annual Meeting Proceedings Part I (June 20 Suppl) 24(18S) (#661), 2006.
6. Arteaga CL, O'Neill A, Moulder SL, Pins M, Sparano JA, Sledge GW, Davidson NE. "Eastern Cooperative Oncology Group, Boston, MA, Combined blockade of the erbB receptor network with trastuzumab and gefitinib (Iressa) in patients (pts) with HER2-overexpressing metastatic breast cancer: A phase I-II ECOG study". Breast Cancer Research and Treatment, 12/2005.
7. Moulder SL, Kazi A, Wright J, Munster P, Vahdat L, Minton S, Hershman D, Diaz N, Malafa M, Riker A, Lee D, Negassa A, Sebti S, Sparano JA. "The farnesyl transferase (FT ase) inhibitor tipifarnib inhibits FT ase in vivo and may enhance the efficacy of neoadjuvant dose-dense doxorubicin-cyclophosphamide (AC) in patients with locally advanced breast cancer (LABC)". Breast Cancer Research and Treatment 94 (Suppl 1) (#5061), 12/2005.
8. Moulder SL, Enkemann S, Dupont E, Riker A, Furman B, Carter WB, Hoover S, Cox C, Eschrich SA, Yeatman T, Diaz N. "The use of DNA microarray to determine potential pathways of tumor cell metastasis". Breast Cancer Research and Treatment 94 (Suppl 1) (#4069), 12/2005.
9. Moulder SL, Munster P, Minton S, Diaz N, Horton J, Rocha Lima C, Hutson L, Sullivan D. "Results of a planned efficacy and safety analysis for a National Comprehensive Cancer Network sponsored phase II study of gemcitabine and irinotecan (GI) in metastatic breast cancer (MBC)". J Clin Oncol, 2005 ASCO Annual Meeting Proceedings, Part I of II (June 1 Suppl) 23(16S) (#679), 2005.
10. Moulder SL, Valkov N, Minton S, Munster P, Lush R, Lacevic M, Sims I, Cammarata A, Horton J, Sullivan D. "A National Comprehensive Cancer Network Phase II study of gemcitabine and irinotecan in metastatic breast cancer: Can topoisomerase I localization predict response to irinotecan?". EORTC Molecular Targets Meeting, 2004.
11. Sparano JA, Hopkins U, Moulder S, Vahdat L. "A phase I trial of the farnesyl transferase inhibitor tipifarnib plus doxorubicin-cyclophosphamide in patients with metastatic breast cancer". J Clin Oncol, 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition) 22(14S (July 15 Suppl)):676, 2004.
12. Blaskovich M, Bucher C, Thai V, Peng H, Carrico D, Moulder S, Hamilton AD, Sebti SM. "Geranylgeranyltransferase I inhibitors induce p27 accumulation and G1 arrest in human breast cancer cell lines independently of Rb status and expression levels of Erb1, 2, 3 and 4". Proceedings of the American Association for Cancer Research, 2004.
13. Munster PN, Mita M, Britten C, Minton S, Moulder S, Noe D, Roedig B, Denis L, Slamon D, Tolcher A. "Phase I and pharmacokinetic (PK) study of CP-724, 714, an oral human epidermal growth factor receptor-2 (HER-2) selective tyrosine kinase inhibitor". J Clin Oncol, 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition) 22(14S (July 15 Suppl)):3082, 2004.
14. Moulder SL, Yakes FM, Bianco R, Arteaga CL. "Small molecule EGF receptor tyrosine kinase inhibitor ZD1839 (IRESSA) inhibits HER2/Neu (erb-2) overexpressing breast tumors cells". Proceedings American Society of Clinical Oncology, 2001 ASCO Annual Meeting 20 (#8), 2001.
15. Moulder SL, Roberts JR, Shumaker RD, Johnson DH. "Histology of synchronous pulmonary nodules". Proceedings of the American Society of Clinical Oncology 19:54a, 2000.
16. Moulder SL, Arrowsmith ER, Stein RS, Goodman SA, Morgan DS, Brandt SJ, Greer JP, Wolff SN. "Prognostic factors in HLA matched related allogeneic transplant for relapsed adult acute myeloid leukemia [abstract] In: Forty-first annual meeting of the American Society of Hematology". New Orleans: American Society of Hematology 94(10):385b, 1999.
17. Megason GC, Moulder SL, Pullen DJ. "The use of in vitro culture assays to predict in vivo response to various treatment modalities in a patient with diamond blackfan anemia". Journal of Cellular Biochemistry 18-A:34, 1994.

Book Chapters
1. Craft BS, Moulder SL. "Targeted therapy in breast cancer.". In: Targeted Therapy in Cancer. Humana Press, 2008.
2. Moulder SL, Arteaga CL. "Receptor tyrosine kinases as therapeutic targets in solid tumors.". In: Chemoradiation in Cancer Therapy. Humana Press, 2004.

Last updated: 10/28/2009